The CYP19/estrogen/GPER pathway modulates EGFR/ERK and HIF-1α/TGF-β1 signaling, all of which have key roles in the proliferation and fibrogenesis of prostatic stromal cells in patients with accelerated clinical progression of BPH (Fig. 7). Here, TGFB1 is linked to benign prostatic hyperplasia.